IL-6、CCL-18表达情况对乳腺癌病理诊断的相关性分析及其临床意义

The Diagnostic Value and Its Mechanism of IL-6 and CCL-18 for Breast Cancer

目的探讨IL-6、CCL^(-1)8表达情况对乳腺癌临床病理诊断的相关性及其作用机制。方法选取2013年3月~2015年6月我院收治的32例乳腺癌患者(乳腺癌组)、28例乳腺良性肿瘤患者(乳腺良性病变组)和30例健康体检者(健康对照组)作为研究对象,采用酶联免疫吸附法(ELISA)测定血清IL-6、CCL^(-1)8水平,比较三组及乳腺癌组不同临床分期血清IL-6、CCL^(-1)8水平,并探讨IL-6、CCL^(-1)8水平与临床病理参数的关系及其意义。结果乳腺癌组和乳腺良性病变组血清IL-6、CCL^(-1)8水平明显高于健康对照组,且乳腺癌组血清IL-6、CCL^(-1)8水平明显高于乳腺良性病变组,差异有统计学意义(P<0.05);乳腺癌组患者血清IL-6、CCL^(-1)8水平随临床分期的增加呈逐渐升高趋势,差异有统计学意义(P<0.05);乳腺癌组血清IL-6水平在TNM分期晚期(Ⅲ~Ⅳ)、淋巴结转移、Ki67≥20%、ER阳性患者中表达明显升高,差异有统计学意义(P<0.05);CCL^(-1)8水平在TNM分期晚期(Ⅲ~Ⅳ)、Ki67≥20%患者中表达明显升高,差异有统计学意义(P<0.05)。结论IL-6、CCL^(-1)8在乳腺癌中呈高表达,可提示患者病情恶化,预后差,并可能参与了乳腺癌的发生和发展。

Objective To investigate the diagnostic value and its mechanism of IL-6 and CCL-18 for breast cancer. Methods 32 pa-tients with breast cancer are selected as research subjects of breast cancer group, 28 patients with benign breast tumor are selected as re-search subjects of benign breast lesions group and 30 healthy subjects are selected as healthy control group were selected as the research subjects in our hospital from March 2013 to June 2015, the levels of IL-6 and CCL-18 in serum was measured by Enzyme linked immuno-sorbent assay （ELISA）, the levels of serum IL-6 and CCL-18 between the three groups and different clinical stages in patients with breast cancer were compared, the relationship between IL-6、 CCL-18 and clinical pathological parameters was also discussed. Results The levels of serum IL-6 and CCL-18 in breast cancer group and benign breast lesions group were significantly higher than healthy control group, and the serum IL-6, CCL-18 levels in the breast cancer group were significantly higher than benign breast lesions group, the difference was sta-tistically significant （P〈0.05）; The levels of serum IL-6 and CCL-18 were increased gradually with the increase of clinical stage in patients with breast cancer, the difference was statistically significant （P〈0.05）; The serum IL-6 level in the late stage of TNM （Ⅲ-Ⅳ）, lymph node metastasis, Ki67 ≥20%, ER positive expression were significantly increased in patients with breast cancer, the difference was statistically significant （P〈0.05）; The serum CCL-18 level in the late stage of TNM （Ⅲ-Ⅳ）、 Ki67 ≥20% were significantly increased in patients with breast cancer, the difference was statistically significant （P〈0.05）. Conclusion The level of IL-6 and CCL-18 were highly expressed in the serum of patients with breast cancer, which suggested that the patient＇s condition deteriorated and the prognosis was poor. The occurrence and development of breast cancer may be related to IL-6 and CCL-18.